Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785242 | 0.85 | CA5A (0.48) | CA5ALMNAKMT2A | |
| SCHEMBL11303214 | 0.85 | CA5A (0.48) | CA5ALMNAKMT2A | |
| SCHEMBL1933748 | 0.82 | HCAR1 (0.55) | CES2CES1HCAR1HCAR2 | |
| SCHEMBL30506535 | 0.82 | HCAR1 (0.55) | CES2CES1HCAR1HCAR2 | |
| SCHEMBL319123 | 0.80 | CES2 (0.62) | CES2CES1CA5AHCAR1HCAR2 | |
| SCHEMBL29821986 | 0.80 | PARP1 (0.52) | CES2CES1HCAR1HCAR2PARP1 | |
| SCHEMBL14120715 | 0.80 | PARP1 (0.52) | CES2CES1HCAR1HCAR2PARP1 | |
| SCHEMBL3764991 | 0.79 | CES2 (0.38) | CES2CES1HCAR1ALDH1A1KMT2A | |
| SCHEMBL2013972 | 0.79 | MAP4K4 (0.39) | CES2CES1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL29821598 | 0.79 | CES2 (0.38) | CES2CES1HCAR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | CES2 3951/4885CES1 2493/4885CA5A 3680/4885 |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | CES2 2440/4885CES1 166/4885CA5A 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.